Cure My Disease

Don't miss your cure!

 Log in / Sign up

Light-Activated nanoparticles could target sarcomas

NCT ID NCT06599957

Recruiting now Knowledge-focused Sponsor: Istituto Ortopedico Rizzoli Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study is developing a new way to deliver chemotherapy directly to sarcoma tumors using tiny particles activated by light through an optic fiber. Researchers will test these nanoparticles on cells and tissue samples from 30 patients with bone or soft tissue sarcomas. The goal is to see if this approach can kill tumor cells more effectively than standard chemotherapy, with the hope of one day treating inoperable tumors or cancer that has spread.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
nanocarriers loaded with chemotherapeutic agents delivered via optoporation (optic fiber)
What this could lead to
If successful, this could lead to a new way to deliver chemotherapy directly to inoperable sarcomas, potentially reducing side effects and improving treatment.
What could go wrong
This is a very early, lab-based study on patient cells, not yet tested in humans. The technology may not work as hoped or may have unforeseen safety issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BONE AND SOFT TISSUE TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bone sarcoma connective and soft tissue neoplasm osteosarcoma sarcoma Soft Tissue Neoplasms soft tissue sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BONE AND SOFT TISSUE TUMORS

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori

    RECRUITING

    Meldola, Emilia-Romagna, 47014, Italy

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Istituto Ortopedico Rizzoli-OSOTT

    RECRUITING

    Bologna, Emilia-Romagna, 40136, Italy

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.